期刊文献+

ADP-核糖基化可逆修饰在DNA损伤应答及癌症治疗中的研究进展 被引量:2

Progress in reversible ADP-ribosylation modification in DNA damage repair and cancer treatment
原文传递
导出
摘要 细胞基因组DNA遭受到各种内外源因素的攻击可以诱发多种类型的DNA损伤.DNA损伤应答系统(DNA damage response,DDR)能及时识别、修复受损的DNA,维持基因组稳定性,避免肿瘤等多种疾病发生.DDR受到多种蛋白质翻译后修饰的严格调控,ADP-核糖基化(ADP-ribosylation)是其中最为重要的修饰类型之一.ADP-核糖基化是一种动态可逆的翻译后修饰,ADP-核糖基化与去核糖基化之间保持动态平衡,精密调控DNA损伤应答过程.鉴于ADP-核糖基化在DNA损伤修复中的独特功能,靶向这一可逆过程的抑制剂已被开发或有望作为一类用于癌症治疗的靶向药物.本文就ADP-核糖基化可逆修饰在DNA损伤修复及癌症治疗中的研究进展进行综述. Cellular genomic DNA is attacked by various internal and external stimuli,inducing multiple types of DNA damage.DNA damage response(DDR)can hastily repair DNA damage,maintain genome stability,and avoid tumors and other diseases.DDR is regulated by diverse protein posttranslational modifications.ADP-ribosylation is one of the most important modifications in DDR.ADPribosylation is a dynamic and reversible posttranslational modification.The dynamic balance between ADP-ribosylation and de-ADPribosylation precisely regulates DDR.Given the unique function of ADP-ribosylation in DNA damage repair,inhibitors targeting this reversible process have been developed and are expected to be a new class of chemotherapeutics for cancer treatment.This review introduces the research progress of reversible ADP-ribosylation modification in DNA damage repair and cancer treatment.
作者 闫珍珍 杨肖云 王亚光 刘秀华 吴琛 YAN ZhenZhen;YANG XiaoYun;WANG YaGuang;LIU XiuHua;WU Chen(DNA Damage Repair Research Center,School of Life Sciences,Hebei University,Baoding 071002,China;Institute of Life Science and Green Development,Hebei University,Baoding 071002,China)
出处 《中国科学:生命科学》 CSCD 北大核心 2021年第9期1218-1228,共11页 Scientia Sinica(Vitae)
基金 国家自然科学基金(批准号:32071277,31670812) 河北省教育厅重点项目(批准号:ZD2020183)资助。
关键词 ADP-核糖基化 去ADP-核糖基化 DNA损伤应答 癌症治疗 ADP-ribosylation de-ADP-ribosylation DNA damage response cancer therapy
  • 相关文献

参考文献5

二级参考文献135

  • 1段光杰,阎晓初,卞修武,李军,陈鑫.β-链接素和基质金属蛋白酶-7在结直肠腺瘤腺癌组织表达的意义[J].中华病理学杂志,2004,33(6):518-522. 被引量:18
  • 2蒋菊香,阮长耿,吴士良.膜型基质金属蛋白酶-1的结构、功能与调节[J].生命的化学,2005,25(6):468-471. 被引量:6
  • 3Ying-Chi Ip,Siu-Tim Cheung,Ka-Ling Leung,Sheung-Tat Fan.Mechanism of metastasis by membrane type 1-matrix metalloproteinase in hepatocellular carcinoma[J].World Journal of Gastroenterology,2005,11(40):6269-6276. 被引量:11
  • 4Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays, 2004, 26: 882-893.
  • 5Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev, 2002, 54: 375-429.
  • 6Ferraris DV. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med Chem, 2010, 53: 4561-4584.
  • 7Huber A, Bai P, de Murcia JM, de Murcia G. PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development. DNA Repair, 2004, 3: 1103-1108.
  • 8Lupo B, Trusolino L. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. BBA-Rev Cancer, 2014, 1846: 201-215.
  • 9Peralta-Leal A, Rodríguez-Vargas JM, Aguilar-Quesada R, Rodríguez MI, Linares JL, de Almodóvar MR, Oliver FJ. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radical Bio Med, 2009, 47: 13-26.
  • 10Langelier MF, Planck JL, Roy S, Pascal JM. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science, 2012, 336: 728-732.

共引文献13

同被引文献20

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部